Real-time assessment of in vivo renal ischemia using laser autofluorescence imaging

2005 ◽  
Vol 10 (4) ◽  
pp. 044018 ◽  
Author(s):  
Jason T. Fitzgerald ◽  
Andromachi Michalopoulou ◽  
Christopher D. Pivetti ◽  
Rajesh N. Raman ◽  
Christoph Troppmann ◽  
...  
Endoscopy ◽  
2016 ◽  
Vol 48 (06) ◽  
pp. 557-562 ◽  
Author(s):  
Timo Rath ◽  
Gian Tontini ◽  
Michael Vieth ◽  
Andreas Nägel ◽  
Markus Neurath ◽  
...  

2009 ◽  
Vol 23 (3) ◽  
pp. 373-378 ◽  
Author(s):  
Sero Andonian ◽  
Tonya Coulthard ◽  
Arthur D. Smith ◽  
Pravin S. Singhal ◽  
Benjamin R. Lee

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e14524-e14524
Author(s):  
Madappa N. Kundranda ◽  
Alexander Koenig ◽  
Julia Beck ◽  
Kirsten Bornemann-Kolatzki ◽  
Jessica Coats ◽  
...  

e14524 Background: Humoral tumor markers are used clinically for real-time assessment of therapeutic efficacy. In pancreatic ductal adenocarcinoma (PDAC) the predominant marker is CA19-9, which is not expressed by 10 to 30% of patients depending on race. We compared plasma cell-free DNA (cfDNA) copy number based assay with changes in serum CA19-9 levels and radiological responses to predict responses to systemic therapy. Methods: In a laboratory blinded, prospective multicenter pilot study, 40 non-resectable PDAC patients, treated with (m)FOLFIRINOX, CAPIRI, or gemcitabine +/- nab-paclitaxel) are currently enrolled. CA19-9 was determined in the local center’s laboratory. Tumor cfDNA was measured with a copy-number instability (CNI) scoring assay, determined by next generation sequencing in a centralized laboratory. The CNI score assesses the amount of cfDNA with somatic macro-alterations originating from malignant neoplasms. The difference of the values before commencing therapy (baseline) and prior to cycle 2 (either rising or falling) was calculated as a predictor of standardized radiological evaluation of chemotherapeutic efficacy. Results: 37 patients (3 drop-outs) had data for baseline and cycle 2, of which CA19-9 was elevated and evaluable in 29 patients. The direction from baseline to cycle 2 of CA19-9 and CNI scores were in agreement in 18/29 patients. 9 of 11 cases with discordant CNI score and CA19-9 had treatment response data, and CNI correlated with 7/9 (78%); in contrast 7/9 had rising CA19-9, when response was stable disease or better (22% concordance). In the 27 patients with available imaging, CNI predicted better (n = 18) than CA19-9 (n = 10) (p = 0.03 Fisher’s exact). Conclusions: This comparative study on cfDNA versus CA19-9 suggest that cfDNA CNI quantitation is a potentially more reliable blood based marker for early real-time assessment of efficacy in systemic PDAC therapy than CA19-9, compared to standard of care imaging. The better prediction after the first cycle might be due to the very short in vivo half-life of cfDNA ( < 1hr) compared to about one week for CA19-9. These results justify a larger prospective validation trial.


2015 ◽  
Vol 81 (5) ◽  
pp. AB158
Author(s):  
Timo Rath ◽  
Michael Vieth ◽  
Martin Grauer ◽  
Andreas Naegel ◽  
Markus F. Neurath ◽  
...  

2021 ◽  
Author(s):  
Peter R. Corridon ◽  
Shurooq H. Karam ◽  
Ali A. Khraibi ◽  
Anousha A. Khan ◽  
Mohamed A. Alhashmi

Abstract Severe renal ischemia-reperfusion injury (IRI) can lead to acute and chronic kidney dysfunction. Cytoskeletal modifications are among the main effects of this condition. The majority of studies that have contributed to the current understanding of IRI have relied on histological analyses using exogenous probes after the fact. Here we report the successful real-time visualization of actin cytoskeletal alterations in live proximal and distal tubules that arise at the onset of severe IRI. To achieve this, we induced fluorescent actin expression in these segments in rats with hydrodynamic gene delivery (HGD). Using intravital two-photon microscopy we then tracked and quantified endogenous actin dysregulation that occurred by subjecting these animals to 60 minutes of bilateral renal ischemia. Rapid (by 1-hour post-reperfusion) and significant (up to 50%) declines in actin content were observed. The decline in fluorescence within proximal tubules was significantly greater than that observed in distal tubules. Actin-based fluorescence was not recovered during the measurement period extending 24 hours post-reperfusion. Such injury decimated the renal architecture, in particular, actin brush borders, and hampered the reabsorptive and filtrative capacities of these tubular compartments. Thus, for the first time, we show that the combination of HGD and intravital microscopy can serve as an experimental tool to better understand how IRI modifies the cytoskeleton in vivo and provide an extension to current histopathological techniques.


2009 ◽  
Vol 181 (4S) ◽  
pp. 807-807
Author(s):  
Sero Andonian ◽  
Tonya Coulthard ◽  
Pravin S Singhal ◽  
Arthur D Smith ◽  
Benajamin R Lee

2003 ◽  
Vol 11 (4) ◽  
pp. 291 ◽  
Author(s):  
Tao Wu ◽  
Jianan Y. Qu ◽  
Tak-Hong Cheung ◽  
Keith Wing-Kit Lo ◽  
Mei-Yung Yu

Sign in / Sign up

Export Citation Format

Share Document